Literature DB >> 22478788

A rich pipeline that needs to be managed.

Keith Bradbury.   

Abstract

Health plans will experience increasing demands as specialty drugs are used for more common conditions. The author discusses ways to manage the ever-changing terrain.

Year:  2009        PMID： 22478788      PMCID： PMC2799093     

Source DB:  PubMed          Journal:  Biotechnol Healthc        ISSN： 1554-169X


  3 in total

1.  Trial watch: BLYS-targeted antibody shows promise in Phase III SLE trial.

Authors: 
Journal:  Nat Rev Drug Discov       Date:  2009-09       Impact factor: 84.694

2.  American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

Authors:  Kenneth G Saag; Gim Gee Teng; Nivedita M Patkar; Jeremy Anuntiyo; Catherine Finney; Jeffrey R Curtis; Harold E Paulus; Amy Mudano; Maria Pisu; Mary Elkins-Melton; Ryan Outman; Jeroan J Allison; Maria Suarez Almazor; S Louis Bridges; W Winn Chatham; Marc Hochberg; Catherine MacLean; Ted Mikuls; Larry W Moreland; James O'Dell; Anthony M Turkiewicz; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2008-06-15

Review 3.  Monitoring of viral levels during therapy of hepatitis C.

Authors:  Gary L Davis
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.